Pharmacological Assessment of M1 Muscarinic Acetylcholine Receptor-Gq/11 Protein Coupling in Membranes Prepared from Postmortem Human Brain Tissue

Using a selective Gαq/11 protein antibody capture guanosine 5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding approach, it has been possible to perform a quantitative pharmacological examination of the functional activity of the M1 muscarinic acetylcholine receptor (mAChR) in membranes prepared from human postmortem cerebral cortex. Oxotremorine-M caused a ≥2-fold increase in [35S]GTPγS-Gαq/11 binding with a pEC50 of 6.06 ± 0.16 in Brodmann's areas 23 and 25 that was almost completely inhibited by preincubation of membranes with the M1 mAChR subtype-selective antagonist muscarinic toxin-7. In addition, the orthosteric and allosteric agonists, xanomeline [3(3-hexyloxy-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine] and AC-42 (4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine hydrogen chloride), increased [35S]-GTPγS-Gαq/11 binding, but with reduced intrinsic activities, inducing maximal responses that were 42 ± 1 and 44 ± 2% of the oxotremorine-M-induced response, respectively. These data indicate that the M1 receptor is the predominant mAChR subtype coupling to the Gαq/11 G protein in these brain regions and that it is possible to quantify the potency and intrinsic activity of full and partial M1 mAChR receptor agonists in postmortem human brain using a selective Gαq/11 protein antibody capture [35S]GTPγS binding assay.

[1]  R A John Challiss,et al.  "Phenotypic" pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology. , 2007, Biochemical pharmacology.

[2]  F. Bymaster,et al.  Towards a muscarinic hypothesis of schizophrenia , 2007, Molecular Psychiatry.

[3]  D. Cussac,et al.  Native Rat Hippocampal 5-HT1A Receptors Show Constitutive Activity , 2007, Molecular Pharmacology.

[4]  M. Hasselmo.  The role of acetylcholine in learning and memory , 2006, Current Opinion in Neurobiology.

[5]  I. Azúa,et al.  Levels of G-protein αq/11 subunits and of phospholipase C-β(1–4), -γ, and -δ1 isoforms in postmortem human brain caudate and cortical membranes: Potential functional implications , 2006, Neurochemistry International.

[6]  B. Dean,et al.  No change in cortical muscarinic M2, M3 receptors or [35S]GTPgammaS binding in schizophrenia. , 2006, Life sciences.

[7]  C. Langmead,et al.  Probing the Molecular Mechanism of Interaction between 4-n-Butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the Muscarinic M1 Receptor: Direct Pharmacological Evidence That AC-42 Is an Allosteric Agonist , 2006, Molecular Pharmacology.

[8]  P. Delmas,et al.  Pathways modulating neural KCNQ/M (Kv7) potassium channels , 2005, Nature Reviews Neuroscience.

[9]  J. Wess,et al.  Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. , 2004, Annual review of pharmacology and toxicology.

[10]  J. Buccafusco,et al.  The Cholinergic Hypothesis of Age and Alzheimer's Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development , 2003, Journal of Pharmacology and Experimental Therapeutics.

[11]  G. Milligan.  Principles: extending the utility of [35S]GTP gamma S binding assays. , 2003, Trends in pharmacological sciences.

[12]  J. Wess,et al.  M1 muscarinic receptor signaling in mouse hippocampus and cortex , 2002, Brain Research.

[13]  U. Hacksell,et al.  Discovery of an ectopic activation site on the M(1) muscarinic receptor. , 2002, Molecular pharmacology.

[14]  J. Wess,et al.  M1 Muscarinic Acetylcholine Receptors Activate Extracellular Signal-Regulated Kinase in CA1 Pyramidal Neurons in Mouse Hippocampal Slices , 2001, Molecular and Cellular Neuroscience.

[15]  B. Dean,et al.  Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. , 2001, The American journal of psychiatry.

[16]  G. W. Price,et al.  Cell type-specific differences in the coupling of recombinant mGlu1α receptors to endogenous G protein sub-populations , 2001, Neuropharmacology.

[17]  I. Azúa,et al.  Regulation of phospholipase Cβ activity by muscarinic acetylcholine and 5-HT2 receptors in crude and synaptosomal membranes from human cerebral cortex , 2001, Neuropharmacology.

[18]  S R Nahorski,et al.  Gq/11 and Gi/o activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor‐subtype , 2001, British journal of pharmacology.

[19]  C. Scott,et al.  5‐HT1A receptor agonist‐antagonist binding affinity difference as a measure of intrinsic activity in recombinant and native tissue systems , 2000, British journal of pharmacology.

[20]  R. Bartus,et al.  On Neurodegenerative Diseases, Models, and Treatment Strategies: Lessons Learned and Lessons Forgotten a Generation Following the Cholinergic Hypothesis , 2000, Experimental Neurology.

[21]  J. González-Maeso,et al.  Characterization of receptor-mediated [35S]GTPgammaS binding to cortical membranes from postmortem human brain. , 2000, European journal of pharmacology.

[22]  D. McClure,et al.  Determination of [35S]guanosine-5'-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay. , 1999, The Journal of pharmacology and experimental therapeutics.

[23]  D. Middlemiss,et al.  Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry , 1999, British journal of pharmacology.

[24]  A. Brown,et al.  In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes. , 1999, European journal of pharmacology.

[25]  A. Levey,et al.  Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  N. Birdsall,et al.  International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. , 1998, Pharmacological reviews.

[27]  A. Levey,et al.  Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  E. Karlsson,et al.  Muscarinic receptor subtype selective toxins. , 1997, Life sciences.

[29]  A. Levey.  Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  G. Celesia,et al.  Regional alterations in M1 muscarinic receptor-G protein coupling in Alzheimer's disease. , 1995, Journal of neuropathology and experimental neurology.

[31]  G. Celesia,et al.  Regional Alterations in M., Muscarinic Receptor-G Protein Coupling in Alzheimer's Disease , 1995 .

[32]  T. Wieland,et al.  Transfected muscarinic acetylcholine receptors selectively couple to Gi-type G proteins and Gq/11. , 1994, Molecular pharmacology.

[33]  D. Wong,et al.  Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. , 1994, The Journal of pharmacology and experimental therapeutics.

[34]  K. Jakobs,et al.  Muscarinic acetylcholine receptor-stimulated binding of guanosine 5'-O-(3-thiotriphosphate) to guanine-nucleotide-binding proteins in cardiac membranes. , 1989, European journal of biochemistry.

[35]  D. Spencer,et al.  Effects of N-ethylmaleimide on muscarinic acetylcholine receptor subtype autoradiography and inositide response in rat brain. , 1986, Life sciences.

[36]  K. Jakobs,et al.  Ni-mediated inhibition of human platelet adenylate cyclase by thrombin. , 1984, European journal of biochemistry.

[37]  P. Sternweis,et al.  Isolation of two proteins with high affinity for guanine nucleotides from membranes of bovine brain. , 1984, The Journal of biological chemistry.

[38]  G. Johnson,et al.  Peptide mapping of adenylate cyclase regulatory proteins that are cholera toxin substrates. , 1980, The Journal of biological chemistry.

[39]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[40]  Alcino J. Silva,et al.  Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice , 2003, Nature Neuroscience.

[41]  D. Flynn,et al.  Different effects of N-ethylmaleimide on M1 and M2 muscarine receptors in rat brain. , 1985, Proceedings of the National Academy of Sciences of the United States of America.